[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fG1AOPVAwe-BVzmJDki144ZUyyEf6F-vxx5iA0O7Z4l0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Astex Pharmaceuticals, Inc.",[4],45,false,0,9,3753,[12,15,18,21,24,27,29,31],{"name":13,"count":14},"Acute Myeloid Leukemia",7,{"name":16,"count":17},"Myelodysplastic Syndromes",5,{"name":19,"count":20},"Pancreatic Cancer",4,{"name":22,"count":23},"Chronic Myelogenous Leukemia",3,{"name":25,"count":26},"Healthy Volunteers",2,{"name":28,"count":26},"Healthy Volunteer",{"name":30,"count":26},"Prostate Cancer",{"name":32,"count":26},"Myelodysplastic Syndrome",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,154,200,260,308,330,352,374,411,430,448,497,535,560,578,603,621,639,663,681,699,717,744,762,780,806,824,851,889,923,947,965,983,1009,1038,1056,1074,1092,1110,1135,1153,1171,1196,1214],{"intervention":43,"totalTrials":44,"cells":45},"rubitecan",11,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":61,"PHASE3":115,"PHASE4":150,"NA":152},{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[50],{"nctId":51,"briefTitle":52,"status":53,"phases":54,"start":55,"enrollment":56,"conditions":57,"interventions":59},"NCT00113113","Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction","COMPLETED",[36],"2001-08",54,[58],"Tumors",[60],"Rubitecan",{"trials":62,"activeCount":8},[63,73,84,92,100,107],{"nctId":64,"briefTitle":65,"status":66,"phases":67,"start":68,"conditions":69,"interventions":72},"NCT00005876","Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery","UNKNOWN",[37],"2000-04",[70,71],"Esophageal Cancer","Gastric Cancer",[43],{"nctId":74,"briefTitle":75,"status":53,"phases":76,"completion":77,"start":78,"conditions":79,"interventions":83},"NCT00005874","Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas",[37],"2004-04","1999-06",[80,81,82],"Gastrointestinal Stromal Tumor","Sarcoma","Small Intestine Cancer",[43],{"nctId":85,"briefTitle":86,"status":66,"phases":87,"start":88,"conditions":89,"interventions":91},"NCT00005877","Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer",[37],"1999-09",[90],"Colorectal Cancer",[43],{"nctId":93,"briefTitle":94,"status":53,"phases":95,"completion":77,"start":96,"conditions":97,"interventions":99},"NCT00005875","Nitrocamptothecin in Treating Patients With Metastatic Melanoma",[37],"1999-01",[98],"Melanoma (Skin)",[43],{"nctId":101,"briefTitle":102,"status":53,"phases":103,"completion":77,"start":88,"conditions":104,"interventions":106},"NCT00005873","Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",[37],[105],"Breast Cancer",[43],{"nctId":108,"briefTitle":109,"status":53,"phases":110,"completion":77,"start":111,"conditions":112,"interventions":114},"NCT00005872","Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer",[37],"1999-05",[113],"Lung Cancer",[43],{"trials":116,"activeCount":8},[117,127,135,142],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"start":123,"enrollment":124,"conditions":125,"interventions":126},"NCT00113256","Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer","TERMINATED",[37,38],"2006-02","2005-02",39,[19],[60],{"nctId":128,"briefTitle":129,"status":66,"phases":130,"start":131,"conditions":132,"interventions":133},"NCT00005869","Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer",[38],"1998-11",[19],[134,43],"gemcitabine hydrochloride",{"nctId":136,"briefTitle":137,"status":66,"phases":138,"start":131,"conditions":139,"interventions":140},"NCT00005871","Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer",[38],[19],[141,43],"fluorouracil",{"nctId":143,"briefTitle":144,"status":66,"phases":145,"start":146,"conditions":147,"interventions":148},"NCT00005870","Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas",[38],"1999-03",[19],[141,134,149,43],"mitomycin C",{"trials":151,"activeCount":8},[],{"trials":153,"activeCount":8},[],{"intervention":155,"totalTrials":20,"cells":156},"decitabine",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":184,"PHASE4":196,"NA":198},{"trials":158,"activeCount":8},[],{"trials":160,"activeCount":8},[],{"trials":162,"activeCount":8},[163,171,178],{"nctId":164,"briefTitle":165,"status":53,"phases":166,"start":167,"enrollment":168,"conditions":169,"interventions":170},"NCT00042016","Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",[37],"2002-07",40,[22],[155],{"nctId":172,"briefTitle":173,"status":53,"phases":174,"primaryCompletion":175,"start":167,"enrollment":168,"conditions":176,"interventions":177},"NCT00042003","Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",[37],"2004-12",[22],[155],{"nctId":179,"briefTitle":180,"status":53,"phases":181,"start":167,"enrollment":168,"conditions":182,"interventions":183},"NCT00041990","Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",[37],[22],[155],{"trials":185,"activeCount":8},[186],{"nctId":187,"briefTitle":188,"status":53,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":195},"NCT00043381","Decitabine Versus Supportive Care in Adults With Advanced-stage MDS",[38],"2002-11","2003-04","2001-04",160,[32],[155],{"trials":197,"activeCount":8},[],{"trials":199,"activeCount":8},[],{"intervention":201,"totalTrials":20,"cells":202},"Guadecitabine",{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":231,"PHASE4":256,"NA":258},{"trials":204,"activeCount":8},[],{"trials":206,"activeCount":8},[],{"trials":208,"activeCount":8},[209,219],{"nctId":210,"briefTitle":211,"status":120,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT03603964","Guadecitabine Extension Study",[37],"2021-10-04","2018-07-18",35,[13,217],"Myeloid Dysplastic Syndrome",[201],{"nctId":220,"briefTitle":221,"status":53,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":230},"NCT01261312","SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)",[36,37],"2016-07-22","2011-01-04",414,[227,228,229],"MDS","CMML","AML",[201],{"trials":232,"activeCount":8},[233,245],{"nctId":234,"briefTitle":235,"status":53,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},"NCT02920008","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",[38],"2020-01-20","2020-06-01","2017-03-16",302,[13],[243,244],"guadecitabine","Treatment Choice",{"nctId":246,"briefTitle":247,"status":53,"phases":248,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":255},"NCT02907359","Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs",[38],"2020-03-31","2020-11-30","2017-01-13",417,[16,254],"Leukemia, Myelomonocytic, Chronic",[201],{"trials":257,"activeCount":8},[],{"trials":259,"activeCount":8},[],{"intervention":261,"totalTrials":23,"cells":262},"SGI-110",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":291,"PHASE4":304,"NA":306},{"trials":264,"activeCount":8},[],{"trials":266,"activeCount":8},[],{"trials":268,"activeCount":8},[269,279],{"nctId":270,"briefTitle":271,"status":53,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT01752933","SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)",[37],"2015-09","2012-12",52,[277],"Hepatocellular Carcinoma",[261],{"nctId":280,"briefTitle":281,"status":53,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT01696032","SGI-110 in Combination With Carboplatin in Ovarian Cancer",[37],"2016-08","2012-09",120,[287],"Ovarian Cancer",[261,289,290],"Treatment of Choice","Carboplatin",{"trials":292,"activeCount":8},[293],{"nctId":294,"briefTitle":295,"status":53,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},"NCT02348489","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",[38],"2018-05-31","2019-06-17","2015-03-19",815,[302],"Leukemia, Myeloid, Acute",[261,244],{"trials":305,"activeCount":8},[],{"trials":307,"activeCount":8},[],{"intervention":134,"totalTrials":26,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":326,"NA":328},{"trials":311,"activeCount":8},[],{"trials":313,"activeCount":8},[],{"trials":315,"activeCount":8},[],{"trials":317,"activeCount":8},[318,322],{"nctId":128,"briefTitle":129,"status":66,"phases":319,"start":131,"conditions":320,"interventions":321},[38],[19],[134,43],{"nctId":143,"briefTitle":144,"status":66,"phases":323,"start":146,"conditions":324,"interventions":325},[38],[19],[141,134,149,43],{"trials":327,"activeCount":8},[],{"trials":329,"activeCount":8},[],{"intervention":244,"totalTrials":26,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":348,"NA":350},{"trials":333,"activeCount":8},[],{"trials":335,"activeCount":8},[],{"trials":337,"activeCount":8},[],{"trials":339,"activeCount":8},[340,344],{"nctId":234,"briefTitle":235,"status":53,"phases":341,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":342,"interventions":343},[38],[13],[243,244],{"nctId":294,"briefTitle":295,"status":53,"phases":345,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":346,"interventions":347},[38],[302],[261,244],{"trials":349,"activeCount":8},[],{"trials":351,"activeCount":8},[],{"intervention":141,"totalTrials":26,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":370,"NA":372},{"trials":355,"activeCount":8},[],{"trials":357,"activeCount":8},[],{"trials":359,"activeCount":8},[],{"trials":361,"activeCount":8},[362,366],{"nctId":136,"briefTitle":137,"status":66,"phases":363,"start":131,"conditions":364,"interventions":365},[38],[19],[141,43],{"nctId":143,"briefTitle":144,"status":66,"phases":367,"start":146,"conditions":368,"interventions":369},[38],[19],[141,134,149,43],{"trials":371,"activeCount":8},[],{"trials":373,"activeCount":8},[],{"intervention":375,"totalTrials":26,"cells":376},"ASTX727",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":391,"PHASE3":393,"PHASE4":407,"NA":409},{"trials":378,"activeCount":8},[],{"trials":380,"activeCount":8},[381],{"nctId":382,"briefTitle":383,"status":120,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT04155580","A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML)",[36],"2022-01-14","2020-06-12",68,[13],[390,375],"ASTX660",{"trials":392,"activeCount":8},[],{"trials":394,"activeCount":8},[395],{"nctId":396,"briefTitle":397,"status":53,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":405},"NCT03306264","Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML",[38],"2021-09-10","2023-05-25","2018-02-15",227,[16,404,13],"Chronic Myelomonocytic Leukemia",[375,406],"Dacogen",{"trials":408,"activeCount":8},[],{"trials":410,"activeCount":8},[],{"intervention":149,"totalTrials":412,"cells":413},1,{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":426,"NA":428},{"trials":415,"activeCount":8},[],{"trials":417,"activeCount":8},[],{"trials":419,"activeCount":8},[],{"trials":421,"activeCount":8},[422],{"nctId":143,"briefTitle":144,"status":66,"phases":423,"start":146,"conditions":424,"interventions":425},[38],[19],[141,134,149,43],{"trials":427,"activeCount":8},[],{"trials":429,"activeCount":8},[],{"intervention":406,"totalTrials":412,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":444,"NA":446},{"trials":433,"activeCount":8},[],{"trials":435,"activeCount":8},[],{"trials":437,"activeCount":8},[],{"trials":439,"activeCount":8},[440],{"nctId":396,"briefTitle":397,"status":53,"phases":441,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":442,"interventions":443},[38],[16,404,13],[375,406],{"trials":445,"activeCount":8},[],{"trials":447,"activeCount":8},[],{"intervention":449,"totalTrials":23,"cells":450},"AT13387",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":466,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":452,"activeCount":8},[],{"trials":454,"activeCount":8},[455],{"nctId":456,"briefTitle":457,"status":53,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":465},"NCT00878423","Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors",[36],"2013-05","2014-03","2008-05",62,[464],"Metastatic Solid Tumors",[449,449],{"trials":467,"activeCount":8},[468,480],{"nctId":469,"briefTitle":470,"status":53,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},"NCT01712217","A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib",[36,37],"2016-12","2017-05-16","2012-10",220,[477],"Non-small Cell Lung Cancer(NSCLC)",[449,479],"Crizotinib",{"nctId":481,"briefTitle":482,"status":53,"phases":483,"primaryCompletion":484,"completion":485,"start":284,"enrollment":486,"conditions":487,"interventions":488},"NCT01685268","A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate",[36,37],"2014-07","2014-12",49,[30],[449,489,490],"abiraterone acetate","Prednisone",{"trials":492,"activeCount":8},[],{"trials":494,"activeCount":8},[],{"trials":496,"activeCount":8},[],{"intervention":498,"totalTrials":26,"cells":499},"Amuvatinib",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":516,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":501,"activeCount":8},[],{"trials":503,"activeCount":8},[504],{"nctId":505,"briefTitle":506,"status":53,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT00894894","Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies",[36],"2008-12","2007-05",22,[512],"Solid Tumors",[514,515],"MP-470","amuvatinib",{"trials":517,"activeCount":8},[518],{"nctId":519,"briefTitle":520,"status":53,"phases":521,"primaryCompletion":522,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":528},"NCT01357395","A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer",[37],"2012-05","2012-05-28","2011-05",23,[527],"Small Cell Lung Carcinoma",[498],{"trials":530,"activeCount":8},[],{"trials":532,"activeCount":8},[],{"trials":534,"activeCount":8},[],{"intervention":536,"totalTrials":412,"cells":537},"pentostatin for",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":539,"activeCount":8},[],{"trials":541,"activeCount":8},[],{"trials":543,"activeCount":8},[544],{"nctId":545,"briefTitle":546,"status":120,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT00032773","Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD",[36,37],"2005-11-03","2002-01-30",36,[552],"Acute Graft Versus Host Disease",[536],{"trials":555,"activeCount":8},[],{"trials":557,"activeCount":8},[],{"trials":559,"activeCount":8},[],{"intervention":479,"totalTrials":412,"cells":561},{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":563,"activeCount":8},[],{"trials":565,"activeCount":8},[],{"trials":567,"activeCount":8},[568],{"nctId":469,"briefTitle":470,"status":53,"phases":569,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":570,"interventions":571},[36,37],[477],[449,479],{"trials":573,"activeCount":8},[],{"trials":575,"activeCount":8},[],{"trials":577,"activeCount":8},[],{"intervention":579,"totalTrials":412,"cells":580},"AT13387 and Imatinib",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":582,"activeCount":8},[],{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[587],{"nctId":588,"briefTitle":589,"status":53,"phases":590,"primaryCompletion":591,"completion":484,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT01294202","A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST",[37],"2013-04","2011-03",26,[595],"Gastrointestinal Stromal Tumor (GIST)",[579],{"trials":598,"activeCount":8},[],{"trials":600,"activeCount":8},[],{"trials":602,"activeCount":8},[],{"intervention":489,"totalTrials":412,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":615,"PHASE4":617,"NA":619},{"trials":606,"activeCount":8},[],{"trials":608,"activeCount":8},[],{"trials":610,"activeCount":8},[611],{"nctId":481,"briefTitle":482,"status":53,"phases":612,"primaryCompletion":484,"completion":485,"start":284,"enrollment":486,"conditions":613,"interventions":614},[36,37],[30],[449,489,490],{"trials":616,"activeCount":8},[],{"trials":618,"activeCount":8},[],{"trials":620,"activeCount":8},[],{"intervention":490,"totalTrials":412,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":624,"activeCount":8},[],{"trials":626,"activeCount":8},[],{"trials":628,"activeCount":8},[629],{"nctId":481,"briefTitle":482,"status":53,"phases":630,"primaryCompletion":484,"completion":485,"start":284,"enrollment":486,"conditions":631,"interventions":632},[36,37],[30],[449,489,490],{"trials":634,"activeCount":8},[],{"trials":636,"activeCount":8},[],{"trials":638,"activeCount":8},[],{"intervention":640,"totalTrials":412,"cells":641},"Decitabine\u002FCedazuridine",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":643,"activeCount":8},[],{"trials":645,"activeCount":8},[],{"trials":647,"activeCount":8},[648],{"nctId":649,"briefTitle":650,"status":120,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":26,"conditions":654,"interventions":655},"NCT05835011","A Study of Oral Decitabine\u002FCedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)",[37],"2023-08-21","2023-06-27",[16],[640,656],"Magrolimab",{"trials":658,"activeCount":8},[],{"trials":660,"activeCount":8},[],{"trials":662,"activeCount":8},[],{"intervention":656,"totalTrials":412,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":666,"activeCount":8},[],{"trials":668,"activeCount":8},[],{"trials":670,"activeCount":8},[671],{"nctId":649,"briefTitle":650,"status":120,"phases":672,"primaryCompletion":652,"completion":652,"start":653,"enrollment":26,"conditions":673,"interventions":674},[37],[16],[640,656],{"trials":676,"activeCount":8},[],{"trials":678,"activeCount":8},[],{"trials":680,"activeCount":8},[],{"intervention":289,"totalTrials":412,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":684,"activeCount":8},[],{"trials":686,"activeCount":8},[],{"trials":688,"activeCount":8},[689],{"nctId":280,"briefTitle":281,"status":53,"phases":690,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":691,"interventions":692},[37],[287],[261,289,290],{"trials":694,"activeCount":8},[],{"trials":696,"activeCount":8},[],{"trials":698,"activeCount":8},[],{"intervention":290,"totalTrials":412,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":702,"activeCount":8},[],{"trials":704,"activeCount":8},[],{"trials":706,"activeCount":8},[707],{"nctId":280,"briefTitle":281,"status":53,"phases":708,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":709,"interventions":710},[37],[287],[261,289,290],{"trials":712,"activeCount":8},[],{"trials":714,"activeCount":8},[],{"trials":716,"activeCount":8},[],{"intervention":718,"totalTrials":412,"cells":719},"ASTX727 Dose Escalation",{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":738,"PHASE4":740,"NA":742},{"trials":721,"activeCount":8},[],{"trials":723,"activeCount":8},[],{"trials":725,"activeCount":8},[726],{"nctId":727,"briefTitle":728,"status":53,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":735},"NCT02103478","Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)",[36,37],"2018-06-05","2019-12-04","2014-10-28",130,[32,227],[718,736,737],"ASTX727 Dose Confirmation","ASTX727 Fixed-Dose Combination",{"trials":739,"activeCount":8},[],{"trials":741,"activeCount":8},[],{"trials":743,"activeCount":8},[],{"intervention":736,"totalTrials":412,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":747,"activeCount":8},[],{"trials":749,"activeCount":8},[],{"trials":751,"activeCount":8},[752],{"nctId":727,"briefTitle":728,"status":53,"phases":753,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":754,"interventions":755},[36,37],[32,227],[718,736,737],{"trials":757,"activeCount":8},[],{"trials":759,"activeCount":8},[],{"trials":761,"activeCount":8},[],{"intervention":737,"totalTrials":412,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":774,"PHASE4":776,"NA":778},{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[],{"trials":769,"activeCount":8},[770],{"nctId":727,"briefTitle":728,"status":53,"phases":771,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":772,"interventions":773},[36,37],[32,227],[718,736,737],{"trials":775,"activeCount":8},[],{"trials":777,"activeCount":8},[],{"trials":779,"activeCount":8},[],{"intervention":781,"totalTrials":412,"cells":782},"AT7519M",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":784,"activeCount":8},[],{"trials":786,"activeCount":8},[],{"trials":788,"activeCount":8},[789],{"nctId":790,"briefTitle":791,"status":53,"phases":792,"primaryCompletion":485,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":798},"NCT01183949","Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma",[36,37],"2015-03","2010-11",18,[797],"Multiple Myeloma",[781,799],"Bortezomib",{"trials":801,"activeCount":8},[],{"trials":803,"activeCount":8},[],{"trials":805,"activeCount":8},[],{"intervention":799,"totalTrials":412,"cells":807},{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":809,"activeCount":8},[],{"trials":811,"activeCount":8},[],{"trials":813,"activeCount":8},[814],{"nctId":790,"briefTitle":791,"status":53,"phases":815,"primaryCompletion":485,"completion":793,"start":794,"enrollment":795,"conditions":816,"interventions":817},[36,37],[797],[781,799],{"trials":819,"activeCount":8},[],{"trials":821,"activeCount":8},[],{"trials":823,"activeCount":8},[],{"intervention":825,"totalTrials":412,"cells":826},"AT9283",{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":828,"activeCount":8},[],{"trials":830,"activeCount":8},[],{"trials":832,"activeCount":8},[833],{"nctId":834,"briefTitle":835,"status":120,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":844},"NCT00522990","Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias",[36,37],"2009-04","2006-09",48,[13,841,842,16,843],"Acute Lymphoblastic Leukemia","Chronic Myeloid Leukemia","Myelofibrosis",[825],{"trials":846,"activeCount":8},[],{"trials":848,"activeCount":8},[],{"trials":850,"activeCount":8},[],{"intervention":390,"totalTrials":23,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":854,"activeCount":8},[],{"trials":856,"activeCount":8},[857,868,877],{"nctId":858,"briefTitle":859,"status":53,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":550,"conditions":864,"interventions":865},"NCT04411030","A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam",[36],"2020-08-23","2020-08-29","2020-05-20",[28],[390,866,867],"Midazolam","Itraconazole",{"nctId":869,"briefTitle":870,"status":53,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":876},"NCT04479800","Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers",[36],"2020-08-25","2020-07-20",21,[28],[390],{"nctId":382,"briefTitle":383,"status":120,"phases":878,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":879,"interventions":880},[36],[13],[390,375],{"trials":882,"activeCount":8},[],{"trials":884,"activeCount":8},[],{"trials":886,"activeCount":8},[],{"trials":888,"activeCount":8},[],{"intervention":890,"totalTrials":26,"cells":891},"SGI-1776",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":893,"activeCount":8},[],{"trials":895,"activeCount":8},[896,906],{"nctId":897,"briefTitle":898,"status":899,"phases":900,"primaryCompletion":901,"completion":901,"start":902,"enrollment":8,"conditions":903,"interventions":905},"NCT01239108","Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed\u002FRefractory Leukemias","WITHDRAWN",[36],"2012-04","2010-10",[904],"Relapsed\u002FRefractory Leukemias",[890],{"nctId":907,"briefTitle":908,"status":120,"phases":909,"primaryCompletion":902,"completion":902,"start":910,"enrollment":911,"conditions":912,"interventions":914},"NCT00848601","Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed\u002FRefractory Non Hodgkin's Lymphoma",[36],"2009-02",14,[30,913],"Non-Hodgkins Lymphoma",[890],{"trials":916,"activeCount":8},[],{"trials":918,"activeCount":8},[],{"trials":920,"activeCount":8},[],{"trials":922,"activeCount":8},[],{"intervention":924,"totalTrials":412,"cells":925},"ASTX029",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":927,"activeCount":8},[],{"trials":929,"activeCount":8},[930],{"nctId":931,"briefTitle":932,"status":53,"phases":933,"primaryCompletion":934,"completion":935,"start":936,"enrollment":795,"conditions":937,"interventions":938},"NCT04466514","A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029",[36],"2020-10-01","2020-10-06","2020-07-23",[25],[924],{"trials":940,"activeCount":8},[],{"trials":942,"activeCount":8},[],{"trials":944,"activeCount":8},[],{"trials":946,"activeCount":8},[],{"intervention":866,"totalTrials":412,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":957,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":950,"activeCount":8},[],{"trials":952,"activeCount":8},[953],{"nctId":858,"briefTitle":859,"status":53,"phases":954,"primaryCompletion":861,"completion":862,"start":863,"enrollment":550,"conditions":955,"interventions":956},[36],[28],[390,866,867],{"trials":958,"activeCount":8},[],{"trials":960,"activeCount":8},[],{"trials":962,"activeCount":8},[],{"trials":964,"activeCount":8},[],{"intervention":867,"totalTrials":412,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":975,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":8},[],{"trials":970,"activeCount":8},[971],{"nctId":858,"briefTitle":859,"status":53,"phases":972,"primaryCompletion":861,"completion":862,"start":863,"enrollment":550,"conditions":973,"interventions":974},[36],[28],[390,866,867],{"trials":976,"activeCount":8},[],{"trials":978,"activeCount":8},[],{"trials":980,"activeCount":8},[],{"trials":982,"activeCount":8},[],{"intervention":984,"totalTrials":412,"cells":985},"TAS1553",{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":987,"activeCount":8},[],{"trials":989,"activeCount":8},[990],{"nctId":991,"briefTitle":992,"status":120,"phases":993,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":1000},"NCT04637009","A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms",[36],"2023-02-20","2020-12-21",20,[13,998,999],"Myeloproliferative Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasm",[984],{"trials":1002,"activeCount":8},[],{"trials":1004,"activeCount":8},[],{"trials":1006,"activeCount":8},[],{"trials":1008,"activeCount":8},[],{"intervention":1010,"totalTrials":412,"cells":1011},"MP-470 + topotecan",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1013,"activeCount":8},[],{"trials":1015,"activeCount":8},[1016],{"nctId":1017,"briefTitle":1018,"status":53,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1025},"NCT00881166","Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors",[36],"2009-12","2007-11",101,[1024],"Malignant Disease",[1010,1026,1027,1028,1029],"MP-470 + docetaxel","MP-470 + erlotinib","MP-470 + paclitaxel\u002Fcarboplatin","MP-470 + carboplatin\u002Fetoposide",{"trials":1031,"activeCount":8},[],{"trials":1033,"activeCount":8},[],{"trials":1035,"activeCount":8},[],{"trials":1037,"activeCount":8},[],{"intervention":1026,"totalTrials":412,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1054},{"trials":1041,"activeCount":8},[],{"trials":1043,"activeCount":8},[1044],{"nctId":1017,"briefTitle":1018,"status":53,"phases":1045,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1046,"interventions":1047},[36],[1024],[1010,1026,1027,1028,1029],{"trials":1049,"activeCount":8},[],{"trials":1051,"activeCount":8},[],{"trials":1053,"activeCount":8},[],{"trials":1055,"activeCount":8},[],{"intervention":1027,"totalTrials":412,"cells":1057},{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1072},{"trials":1059,"activeCount":8},[],{"trials":1061,"activeCount":8},[1062],{"nctId":1017,"briefTitle":1018,"status":53,"phases":1063,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1064,"interventions":1065},[36],[1024],[1010,1026,1027,1028,1029],{"trials":1067,"activeCount":8},[],{"trials":1069,"activeCount":8},[],{"trials":1071,"activeCount":8},[],{"trials":1073,"activeCount":8},[],{"intervention":1028,"totalTrials":412,"cells":1075},{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1090},{"trials":1077,"activeCount":8},[],{"trials":1079,"activeCount":8},[1080],{"nctId":1017,"briefTitle":1018,"status":53,"phases":1081,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1082,"interventions":1083},[36],[1024],[1010,1026,1027,1028,1029],{"trials":1085,"activeCount":8},[],{"trials":1087,"activeCount":8},[],{"trials":1089,"activeCount":8},[],{"trials":1091,"activeCount":8},[],{"intervention":1029,"totalTrials":412,"cells":1093},{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1095,"activeCount":8},[],{"trials":1097,"activeCount":8},[1098],{"nctId":1017,"briefTitle":1018,"status":53,"phases":1099,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1100,"interventions":1101},[36],[1024],[1010,1026,1027,1028,1029],{"trials":1103,"activeCount":8},[],{"trials":1105,"activeCount":8},[],{"trials":1107,"activeCount":8},[],{"trials":1109,"activeCount":8},[],{"intervention":1111,"totalTrials":412,"cells":1112},"Cedazuridine",{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1114,"activeCount":8},[],{"trials":1116,"activeCount":8},[1117],{"nctId":1118,"briefTitle":1119,"status":53,"phases":1120,"primaryCompletion":1121,"completion":1122,"start":1123,"enrollment":550,"conditions":1124,"interventions":1125},"NCT04953923","Thorough QT Assessment of Cedazuridine in Healthy Subjects",[36],"2021-11-15","2021-11-16","2021-07-01",[25],[1111,1126],"Moxifloxacin",{"trials":1128,"activeCount":8},[],{"trials":1130,"activeCount":8},[],{"trials":1132,"activeCount":8},[],{"trials":1134,"activeCount":8},[],{"intervention":1126,"totalTrials":412,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1138,"activeCount":8},[],{"trials":1140,"activeCount":8},[1141],{"nctId":1118,"briefTitle":1119,"status":53,"phases":1142,"primaryCompletion":1121,"completion":1122,"start":1123,"enrollment":550,"conditions":1143,"interventions":1144},[36],[25],[1111,1126],{"trials":1146,"activeCount":8},[],{"trials":1148,"activeCount":8},[],{"trials":1150,"activeCount":8},[],{"trials":1152,"activeCount":8},[],{"intervention":514,"totalTrials":412,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1156,"activeCount":8},[],{"trials":1158,"activeCount":8},[1159],{"nctId":505,"briefTitle":506,"status":53,"phases":1160,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":1161,"interventions":1162},[36],[512],[514,515],{"trials":1164,"activeCount":8},[],{"trials":1166,"activeCount":8},[],{"trials":1168,"activeCount":8},[],{"trials":1170,"activeCount":8},[],{"intervention":1172,"totalTrials":412,"cells":1173},"ASTX727 + Day 2 Food",{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1175,"activeCount":8},[],{"trials":1177,"activeCount":8},[1178],{"nctId":1179,"briefTitle":1180,"status":53,"phases":1181,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":795,"conditions":1185,"interventions":1186},"NCT03813186","Effect of Food on Blood Levels of ASTX727",[36],"2019-06-14","2019-12-16","2018-11-08",[16,404,13],[1172,1187],"ASTX727 + Day 4 Food",{"trials":1189,"activeCount":8},[],{"trials":1191,"activeCount":8},[],{"trials":1193,"activeCount":8},[],{"trials":1195,"activeCount":8},[],{"intervention":1187,"totalTrials":412,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1199,"activeCount":8},[],{"trials":1201,"activeCount":8},[1202],{"nctId":1179,"briefTitle":1180,"status":53,"phases":1203,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":795,"conditions":1204,"interventions":1205},[36],[16,404,13],[1172,1187],{"trials":1207,"activeCount":8},[],{"trials":1209,"activeCount":8},[],{"trials":1211,"activeCount":8},[],{"trials":1213,"activeCount":8},[],{"intervention":1215,"totalTrials":412,"cells":1216},"multitargeted receptor tyrosine kinase inhibitor MP470",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1218,"activeCount":8},[],{"trials":1220,"activeCount":8},[],{"trials":1222,"activeCount":8},[],{"trials":1224,"activeCount":8},[],{"trials":1226,"activeCount":8},[],{"trials":1228,"activeCount":8},[1229],{"nctId":1230,"briefTitle":1231,"status":120,"phases":1232,"primaryCompletion":508,"completion":1233,"start":509,"enrollment":1234,"conditions":1235,"interventions":1238},"NCT00504205","MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma",[40],"2010-03",30,[1236,1237],"Lymphoma","Unspecified Adult Solid Tumor, Protocol Specific",[1215]]